LncRNA HORAS5 Promotes Taxane Resistance in Castration-Resistant Prostate Cancer via a BCL2A1-Dependent Mechanism

References

• Chandrasekar T , YangJ , GaoA , EvansCP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl. Androl. Urol.4(3), 365–380 (2015).
   PubMed Web of Science ®Google Scholar
• Gao L , SchwartzmanJ , GibbsAet al. Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS ONE8(5), 1–10 (2013).
   Web of Science ®Google Scholar
• Karantanos T , CornPG , ThompsonTC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene32(49), 5501–5511 (2013).
   PubMed Web of Science ®Google Scholar
• Kirby M , HirstC , CrawfordED. Characterising the castration-resistant prostate cancer population: a systematic review. Int. J. Clin. Pract.65(11), 1180–1192 (2011).
   PubMed Web of Science ®Google Scholar
• Beer TM , ArmstrongAJ , RathkopfDEet al. Enzalutamide in metastatic prostate cancer patients before chemotherapy. N. Engl. J. Med.371(5), 424–433 (2014).
   PubMed Web of Science ®Google Scholar
• Ryan CJ , SmithMR , DeBono JSet al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med.368(2), 138–148 (2013).
   PubMed Web of Science ®Google Scholar
• Petrylak DP , TangenCM , HussainMHAet al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med.351(15), 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• De Bono JS , OudardS , OzgurogluMet al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet376(9747), 1147–1154 (2010).
   PubMed Web of Science ®Google Scholar
• Iyer MK , NiknafsYS , MalikRet al. The landscape of long noncoding RNAs in the human transcriptome. Nat. Genet.47(3), 199–208 (2015).
   PubMed Web of Science ®Google Scholar
• Zampetaki A , AlbrechtA , SteinhofelK. Long non-coding RNA structure and function: is there a link?Front. Physiol.9(AUG), 1–8 (2018).
   PubMedGoogle Scholar
• Cao T , JiangY , WangZet al. H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas. Oncogene38(7), 5356–5366 (2019).
   PubMedGoogle Scholar
• Shan Y , MaJ , PanY , HuJ , LiuB , JiaL. LncRNA SNHG7 sponges MIR-216b to promote proliferation and liver metastasis of colorectal cancer through upregulating GALNT1. Cell Death Dis.9(7), 1–13 (2018).
   PubMedGoogle Scholar
• Wang Y , ZhangL , ZhengXet al. Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis. Cancer Lett.382(2), 137–146 (2016).
   PubMed Web of Science ®Google Scholar
• Chalei V , SansomSN , KongLet al. The long non-coding RNA Dali is an epigenetic regulator of neural differentiation. Elife3, 1–24 (2014).
   Web of Science ®Google Scholar
• Zhai W , ZhuR , MaJet al. A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma. Mol. Cancer18(1), 1–15 (2019).
   PubMedGoogle Scholar
• Malek R , GajulaR , WilliamsRet al. TWIST1-WDR5-Hottip regulates Hoxa9 chromatin to facilitate prostate cancer metastasis. Cancer Res.77(12), 3181–3193 (2017).
   PubMed Web of Science ®Google Scholar
• Li P , ZhangX , WangHet al. MALAT1 Is associated with poor response to oxaliplatin-based chemotherapy in colorectal cancer patients and promotes chemoresistance through EZH2. Mol. Cancer Ther.16(4), 739–751 (2017).
   PubMed Web of Science ®Google Scholar
• Tan DSW , ChongFT , LeongHSet al. Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. Nat. Med.23(10), 1167–1175 (2017).
   PubMed Web of Science ®Google Scholar
• Pucci P , RescignoP , SumanasuriyaS , de BonoJ , CreaF. Hypoxia and Noncoding RNAs in taxane resistance. Trends Pharmacol. Sci.39(8), 695–709 (2018).
   PubMed Web of Science ®Google Scholar
• Huang K-C , RaoPH , LauCCet al. Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol. Cancer Ther.1(10), 769–776 (2002).
   PubMed Web of Science ®Google Scholar
• Xu M , ZhouK , WuY , WangL , LuS. Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA-128 and modulating MAPK1. Mol. Carcinog.58(4), 577–587 (2019).
   PubMed Web of Science ®Google Scholar
• Parolia A , VenalainenE , XueHet al. The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program. Mol. Oncol.13(5), 1121–1136 (2019).
   PubMed Web of Science ®Google Scholar
• Xu L-C , ChenQ-N , LiuX-Qet al. Up-regulation of LINC00161 correlates with tumor migration and invasion and poor prognosis of patients with hepatocellular carcinoma. Oncotarget8(34), 56168–56173 (2017).
   PubMedGoogle Scholar
• Sedelaar JPM , IsaacsJT. Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate69(16), 1724–1729 (2009).
   PubMed Web of Science ®Google Scholar
• Tsaur I , HeideggerI , KretschmerAet al. Aggressive variants of prostate cancer – are we ready to apply specific treatment right now? Cancer Treat. Rev. 75(December 2018), 20–26 (2019).
   PubMedGoogle Scholar
• Beltran H , TomlinsS , AparicioAet al. Aggressive variants of castration resistant prostate cancer. Clin. Cancer Res.20(11), 2846–2850 (2014).
   PubMed Web of Science ®Google Scholar
• Denning W , DasS , GuoS , XuJ , KappesJ , HelZ. Optimization of the transductional efficiency of lentiviral vectors: effect of sera and polycations. Mol. Biotechnol.53(3), 308–314 (2013).
   PubMed Web of Science ®Google Scholar
• Hattori Y , YoshiikeY , HondaM , OhnoH , OnishiH. Evaluation of small interfering RNA delivery into cells by reverse transfection in suspension with cationic liposomes. Pharmacol Pharmacy8, 12 (2017).
   Google Scholar
• Mukhtar E , AdhamiVM , SiddiquiIA , VermaAK , MukhtarH. Fisetin enhances chemotherapeutic effect of cabazitaxel against human prostate cancer cells. Mol. Cancer Ther.15(12), 2863–2874 (2016).
   PubMed Web of Science ®Google Scholar
• Ríos-Colón L , Cajigas-DuRoss CK , BasuAet al. Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes. Oncotarget8(15), 24915–24931 (2017).
   PubMedGoogle Scholar
• Yadav SS , LiJ , StockertJAet al. Combination effect of therapies targeting the PI3K- and ARsignaling pathways in prostate cancer. Oncotarget7(46), 76181–76196 (2016).
   PubMedGoogle Scholar
• McPherson RAC , GalettisPT , de SouzaPL. Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. Br. J. Cancer100(4), 649–655 (2009).
   PubMed Web of Science ®Google Scholar
• Varbiro G , VeresB , GallyasFJ , SumegiB. Direct effect of Taxol on free radical formation and mitochondrial permeability transition. Free Radic. Biol. Med.31(4), 548–558 (2001).
   PubMed Web of Science ®Google Scholar
• Kumar A , ColemanI , MorrisseyCet al. Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer. Nat. Med.22(4), 369–378 (2016).
   PubMed Web of Science ®Google Scholar
• Scher H , FizaziK , SaadFet al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med.367(13), 1187–1197 (2012).
   PubMed Web of Science ®Google Scholar
• Hussain M , FizaziK , SaadFet al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N. Engl. J. Med.378(26), 2465–2474 (2018).
   PubMed Web of Science ®Google Scholar
• Smiyun G , AzarenkoO , MillerHet al. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel. Cancer Chemother. Pharmacol.80(1), 151–164 (2017).
   PubMed Web of Science ®Google Scholar
• Sissung TM , PriceDK , DelRe Met al. Genetic variation: effect on prostate cancer. Biochim. Biophys. Acta1846, 446–456 (2014).
   PubMed Web of Science ®Google Scholar
• Aparicio AM , HarzstarkAL , CornPGet al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin. Cancer Res.19(13), 3621–3630 (2013).
   PubMed Web of Science ®Google Scholar
• Fléchon A , PouesselD , FerlayCet al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: Results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann. Oncol.22, 2476–2481 (2011).
   PubMed Web of Science ®Google Scholar
• Gibbons JA , OuatasT , KrauwinkelWet al. Clinical pharmacokinetic studies of enzalutamide. Clin. Pharmacokinet.54, 1043–1055 (2015).
   PubMed Web of Science ®Google Scholar
• Kern W , BraessJ , FriedrichsenS , KaufmannCC , SchleyerE , HiddemannW. Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: impact of age and renal function on area under the curve. J. Cancer Res. Clin. Oncol.127, 64–68 (2001).
   PubMed Web of Science ®Google Scholar
• Fukuda M , OkaM , SodaHet al. Phase I study of Irinotecan combined with carboplatin in previously untreated solid cancers. Clin. Cancer Res.5(12), 3963–3969 (1999).
   PubMed Web of Science ®Google Scholar
• Diéras V , LortholaryA , LaurenceVet al. Cabazitaxel in patients with advanced solid tumours: results of a Phase i and pharmacokinetic study. Eur. J. Cancer49(1), 25–34 (2013).
   PubMed Web of Science ®Google Scholar
• Song W , KwonGY , KimJHet al. Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer. Oncotarget7(50), 83735–83743 (2016).
   PubMedGoogle Scholar
• Zhang C yang , QiY , LiX nanet al. The role of CCL20/CCR6 axis in recruiting Treg cells to tumor sites of NSCLC patients. Biomed. Pharmacother.69, 242–248 (2015).
   PubMed Web of Science ®Google Scholar
• Chen W , QinY , WangDet al. CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. PLoS Biol.16(7), 1–27 (2018).
   Web of Science ®Google Scholar
• Haq R , YokoyamaS , HawrylukEBet al. BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc. Natl Acad. Sci. USA110(11), 4321–4326 (2013).
   PubMed Web of Science ®Google Scholar
• Champa D , RussoMA , LiaoX-H , RefetoffS , GhosseinRA , DiCristofano A. Obatoclax overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression. Endocr. Relat. Cancer21(5), 755–767 (2014).
   PubMed Web of Science ®Google Scholar
• Lionnard L , DucP , BrennanMSet al. TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1. Cell Death Differ.26(5), 902–917 (2019).
   PubMed Web of Science ®Google Scholar
• Jenal M , BatlinerJ , ReddyVAet al. The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1. Leukemia24(5), 1073–1076 (2010).
   PubMed Web of Science ®Google Scholar
• Beer TM , HotteSJ , SaadFet al. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, Phase III trial. Lancet Oncol.18(11), 1532–1542 (2017).
   PubMed Web of Science ®Google Scholar
• Bellmunt J , EiglBJ , SenkusEet al. Borealis-1: a randomized, first-line, placebo-controlled, Phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. Ann. Oncol.28(10), 2481–2488 (2017).
   PubMed Web of Science ®Google Scholar
• Yu EY , EllardS , HotteSJet al. A randomized Phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. Invest. New Drugs36(2), 278–287 (2018).
   PubMed Web of Science ®Google Scholar
• Pan Y , ZhangY , LiuWet al. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p. Cell Death Dis.10(2), 1–14 (2019).
   Google Scholar
• Si X , ZangR , ZhangEet al. LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. Oncotarget7(49), 81452–81462 (2016).
   PubMedGoogle Scholar
• Fu Y , WangW , LiXet al. LncRNA H19 interacts with S-adenosylhomocysteine hydrolase to regulate LINE-1 Methylation in human lung-derived cells exposed to Benzo[a]pyrene. Chemosphere207, 84–90 (2018).
   PubMed Web of Science ®Google Scholar
• Richards L . Prostate cancer: cabazitaxel boosts post-docetaxel survival. Nat. Rev. Urol.7(12), 645 (2010).
   PubMedGoogle Scholar
• Chen X , XieR , GuPet al. Long noncoding RNA LBCs inhibits self-renewal and chemoresistance of bladder cancer stem cells through epigenetic silencing of SOX2. Clin Cancer Res.25(4), 1389–1403 (2019).
   PubMed Web of Science ®Google Scholar
• Miao H , WangL , ZhanHet al. A long noncoding RNA distributed in both nucleus and cytoplasm operates in the PYCARD-regulated apoptosis by coordinating the epigenetic and translational regulation. PLoS Genet.15(5), e1008144 (2019).
   PubMed Web of Science ®Google Scholar
• Zong L , HattoriN , YasukawaYet al. LINC00162 confers sensitivity to 5-Aza-2′-deoxycytidine via modulation of an RNA splicing protein, HNRNPH1. Oncogene38(26), 5281–5293 (2019).
   PubMed Web of Science ®Google Scholar
• Vaughan EE , DeanDA. Intracellular trafficking of plasmids during transfection is mediated by microtubules. Mol. Ther.13(2), 422–428 (2006).
   PubMed Web of Science ®Google Scholar
• Van Gaal EVB , OostingRS , Van EijkRet al. DNA nuclear targeting sequences for non-viral gene delivery. Pharm. Res.28(7), 1707–1722 (2011).
   PubMed Web of Science ®Google Scholar
• Huang W , SuG , HuangXet al. Long noncoding RNA PCAT6 inhibits colon cancer cell apoptosis by regulating anti-apoptotic protein ARC expression via EZH2. Cell Cycle.18(1), 69–83 (2019).
   PubMed Web of Science ®Google Scholar
• Misawa A , TakayamaKI , FujimuraT , HommaY , SuzukiY , InoueS. Androgen-induced lncRNA POTEF-AS1 regulates apoptosis-related pathway to facilitate cell survival in prostate cancer cells. Cancer Sci.108(3), 373–379 (2017).
   PubMed Web of Science ®Google Scholar
• Yu S , WuC , TanQ , LiuH. Long noncoding RNA H19 promotes chemotherapy resistance in choriocarcinoma cells. J. Cell. Biochem.120(9), 15131–15144 (2019).
   PubMed Web of Science ®Google Scholar
• Chen S , XiaX. Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335–c-Met. J. Cell. Physiol.1–11 (2019).
   Web of Science ®Google Scholar
• Komura K , JeongSH , HinoharaKet al. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. Proc. Natl Acad. Sci. USA113(22), 6259–6264 (2016).
   PubMed Web of Science ®Google Scholar
• Martin SK , BanuelosCA , SadarMD , KyprianouN. N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. Mol. Oncol.9(3), 628–639 (2015).
   Web of Science ®Google Scholar
• Shiota M , KashiwagiE , YokomizoAet al. Interaction between docetaxel resistance and castration resistance in prostate cancer: Implications of Twist1, YB-1, and androgen receptor. Prostate73(12), 1336–1344 (2013).
   PubMed Web of Science ®Google Scholar
• Vogler M . BCL2A1: the underdog in the BCL2 family. Cell Death Differ.19(1), 67–74 (2012).
   PubMed Web of Science ®Google Scholar
• Ye Y , ShenA , LiuA. Long non-coding RNA H19 and cancer: a competing endogenous RNA. Bull. Cancer106(12), 1152–1159 (2019).
   PubMed Web of Science ®Google Scholar